Skip to navigation

Clinical Trials

Mirati Therapeutics is developing drug candidates aimed at specific genetic mutations that, based on research, we believe are drivers of cancer progression. Mirati's clinical programs use genomic tests that look for genetic mutations in a patient's tumor that Mirati's drug candidates are designed to target. This strategy allows Mirati to identify the precise group of patients who may respond to the investigational treatments. Some patients in clinical trials may experience medical benefit and some may not.

FIND AN ACTIVE TRIAL – MIRATI STUDY LOCATOR

Image: Trifold Pipeline Chart

Non-Small Cell Lung Cancer

Image: Glesatinib (MGCD265)

The targeting of defined genetic mutations that drive lung cancer progression has proven to be an effective treatment strategy in lung cancer. A number of cancer centers routinely analyze the DNA of lung cancer cells as part of the diagnosis and treatment strategy. This increase of genomic information has led to the discovery of more genetic mutations that may be drivers of lung cancer, which has opened doors to new approaches to treatment aimed specifically at those genetic mutations.

Mirati has two drug candidates in clinical trials to test the safety and efficacy of those candidates in patients with non-small cell lung cancer.

Indications: Non-Small Cell Lung Cancer
Drug Candidate: Glesatinib (MGCD265)
 
Driver Mutations: MET, Axl

A Phase 1B/2 study evaluating the effects of Glesatinib (MGCD265) as a treatment for non-small cell lung cancer patients whose tumors carry genetic alterations of MET and Axl. Mirati and/or participating trial sites will analyze the molecular profile of the tumors of eligible patients to determine if selected mutations are present before enrolling in the clinical trial.



Indications: Non-Small Cell Lung Cancer
Drug Candidate: Sitravatinib (MGCD516)
 
Driver Mutations: RET, CHR4q12, CBL, Trk, DDR

A Phase 1B expansion study evaluating the effects of Sitravatinib (MGCD516) as a treatment for patients with non-small cell lung cancer whose tumors carry genetic alterations of RET, CHR4q12, CBL, Trk, and DDR. Participating trial sites will analyze the genetic sequence of the tumors of eligible patients to determine if those mutations are present before patients enroll in the clinical trial.


 

Mirati is seeking collaborations with investigators and clinical sites interested in exploring program combinations and novel approaches to targeted cancer therapy. For more information, contact bd@mirati.com.

This information is not intended to replace the informed medical advice or medical treatments of a health care professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient or whether enrollment in a clinical trial is appropriate for a patient. If you have questions regarding appropriate treatment of your medical condition, you must consult a suitably qualified healthcare professional.